Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes
- 1 February 2005
- journal article
- research article
- Published by Elsevier BV in Neuroscience Letters
- Vol. 374 (2), 81-86
- https://doi.org/10.1016/j.neulet.2004.10.018
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- A Genome Scan for Modifiers of Age at Onset in Huntington Disease: The HD MAPS StudyAmerican Journal of Human Genetics, 2003
- Modulation of age at onset in Huntington's disease and spinocerebellar ataxia type 2 patients originated from eastern IndiaNeuroscience Letters, 2003
- Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington diseaseAmerican Journal of Medical Genetics Part A, 2003
- The codon 72 polymorphic variants of p53 have markedly different apoptotic potentialNature Genetics, 2003
- Protein aggregation in Huntington’s diseaseBiochimie, 2002
- The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesisProceedings of the National Academy of Sciences of the United States of America, 2001
- Expression of Brain-Derived Neurotrophic Factor in Cortical Neurons Is Regulated by Striatal Target AreaJournal of Neuroscience, 2001
- A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICADNature, 1998
- Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease.Proceedings of the National Academy of Sciences, 1996
- Molecular analysis of late onset Huntington's disease.Journal of Medical Genetics, 1993